BAYZED HEALTH2609.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, BAYZED HEALTH (2609.HK) trades at a P/E of 108.00x, P/B of 2.00x, P/S of 2.71x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 14th percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 94th percentile within its industry and the 95th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B long-window percentiles differ by only 12.9 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. BAYZED HEALTH operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2609 · SEHK: 2609 · 2609
Want the full picture on whether BAYZED HEALTH (2609.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 108.00 | ||||||
| P/B (MRQ) | 2.00 | ||||||
| P/S (TTM) | 2.71 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |